Overview

Phase I Study to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

Status:
Completed

Trial end date:
2022-11-09

Target enrollment:

Participant gender:

Summary

To evaluate the safety and the pharmacokinetics of the JP-1366 20 mg tablet and capsule oral administration in healthy adult volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Onconic Therapeutics Inc.